Xeris Biopharma Holdings, Inc. (XERS)
Valuation Overview•Is Xeris Biopharma Holdings, Inc. Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Moderate quality score of 67/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Solid fundamental quality, though solvency presents a headwind.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
XERS demonstrates strong business quality with robust profitability and healthy margins (highlighted by a massive 33.8% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($73M) and minimal debt risk.
The company is driving exceptional top-line expansion (38.3% 3Y CAGR) paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 11.4%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $83.1M | +43.7% | +38.3% | +70.2% | — | |
| EBITDA | $11.1M | — | — | — | — | |
| Net Income | $2.2M | +101.0% | — | — | — | |
| EPS (Diluted) | $0.01 | +100.9% | — | — | — | |
| Free Cash Flow | $9.5M | +173.8% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 81.6% | 82.0% | 79.7% | 79.1% |
| Operating Margin | 11.4% | -11.6% | -68.3% | -1059.6% |
| Net Margin | 3.8% | -21.6% | -79.6% | -1083.0% |
| FCF Margin | 15.0% | -13.0% | -68.3% | -926.2% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.00 | $0.01 | +465.0% | ||
| Q1'26 | $0.03 | $0.06 | +100.0% | ||
| Q4'25 | $0.01 | $0.00 | -65.0% | ||
| Q3'25 | $-0.03 | $-0.01 | +66.7% | ||
| Q2'25 | $-0.07 | $-0.06 | +14.3% | ||
| Q1'25 | $-0.08 | $-0.03 | +62.5% | ||
| Q4'24 | $-0.09 | $-0.06 | +33.3% | ||
| Q3'24 | $-0.11 | $-0.10 | +9.1% |
Total return is +58.8% (1Y), outperforming the benchmark by +38.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +0.7% | -6.6% | — |
| 1Y | +58.8% | +38.0% | — |
| 3YCAGR | +41.5% | +15.6% | — |
| 5YCAGR | +11.4% | +1.5% | — |
| 10YCAGR | -9.6% | -23.5% | — |
The S&P 500 is at 30.5x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Xeris Biopharma Holdings, Inc. (XERS) valuation, health, and returns.
Xeris Biopharma Holdings, Inc. is estimated to be fair under our discounted cash flow framework. relative multiples indicate the stock is Expensive versus peers compared to industry peers. trading near fair value (DCF: $6.01)
Xeris Biopharma Holdings, Inc. has multiple valuation anchors: DCF Intrinsic Value: $6.01 | Peer Relative Fair Value: $4.90 | Wall Street Analyst Target: $8.82 (implying +19.2% upside). A convergence of these signals offers higher conviction.
Xeris Biopharma Holdings, Inc. displays good financial health with a composite quality score of 67/100, supported by a Altman Z-Score of 0.3 (distress zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 33.8%.
Xeris Biopharma Holdings, Inc. returns capital via buybacks instead of dividends, carrying a 0.9% buyback yield and reducing outstanding shares by +17.7% in the last 12 months.
Xeris Biopharma Holdings, Inc.'s current growth trajectory is Accelerating. The company achieved +43.7% 1Y revenue growth and +100.9% 1Y EPS growth, compared to its 3Y revenue CAGR of +38.3%.
Wall Street consensus is Buy based on 10 analysts, beating EPS expectations in 67% of recent quarters with a 2-quarter streak. The consensus price target represents a +19.2% change from current levels.
Investment risks for Xeris Biopharma Holdings, Inc. include: -46.6% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.89x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.